AstraZeneca Gets US License for Imfinzi Lung-Cancer Drug

Date : 11/29/2019 @ 7:43AM
Source : Dow Jones News
Stock : Astrazeneca Plc (AZN)
Quote : 7878.0  171.0 (2.22%) @ 4:35PM
Astrazeneca share price Chart

AstraZeneca Gets US License for Imfinzi Lung-Cancer Drug

Astrazeneca (LSE:AZN)
Historical Stock Chart

2 Months : From Nov 2019 to Jan 2020

Click Here for more Astrazeneca Charts.
   By Sabela Ojea 

AstraZeneca PLC (AZN.LN) said Friday that a supplemental biologics license application and granted priority review for the Imfinzi drug, which fights against untreated extensive-stage small-cell lung cancer, has been accepted by the U.S. Food and Drug Administration.

The drug maker said a prescription-drug user fee act date--the deadline for the FDA to review the application--is set for the first quarter of 2020.

Small-cell lung cancer is an aggressive, fast-growing form of lung cancer that recurs and progresses rapidly, the London-listed company said.


Write to Sabela Ojea at; @sabelaojeaguix


(END) Dow Jones Newswires

November 29, 2019 02:28 ET (07:28 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20200117 20:35:44